235 related articles for article (PubMed ID: 16596777)
1. Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches.
Reggio PH
Handb Exp Pharmacol; 2005; (168):247-81. PubMed ID: 16596777
[TBL] [Abstract][Full Text] [Related]
2. Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors.
Reggio PH
Curr Pharm Des; 2003; 9(20):1607-33. PubMed ID: 12871061
[TBL] [Abstract][Full Text] [Related]
3. Indoles and related compounds as cannabinoid ligands.
Manera C; Tuccinardi T; Martinelli A
Mini Rev Med Chem; 2008 Apr; 8(4):370-87. PubMed ID: 18473928
[TBL] [Abstract][Full Text] [Related]
4. Structural requirements for cannabinoid receptor probes.
Thakur GA; Nikas SP; Li C; Makriyannis A
Handb Exp Pharmacol; 2005; (168):209-46. PubMed ID: 16596776
[TBL] [Abstract][Full Text] [Related]
5. CB1 and CB2 cannabinoid receptor binding studies based on modeling and mutagenesis approaches.
Ortega-Gutiérrez S; López-Rodríguez ML
Mini Rev Med Chem; 2005 Jul; 5(7):651-8. PubMed ID: 16026311
[TBL] [Abstract][Full Text] [Related]
6. Ligand-ligand and ligand-receptor approaches to modeling the cannabinoid CB1 and CB2 receptors: achievements and challenges.
Reggio PH
Curr Med Chem; 1999 Aug; 6(8):665-83. PubMed ID: 10469885
[TBL] [Abstract][Full Text] [Related]
7. Comparative molecular dynamics simulations of the potent synthetic classical cannabinoid ligand AMG3 in solution and at binding site of the CB1 and CB2 receptors.
Durdagi S; Reis H; Papadopoulos MG; Mavromoustakos T
Bioorg Med Chem; 2008 Aug; 16(15):7377-87. PubMed ID: 18595717
[TBL] [Abstract][Full Text] [Related]
8. Modeling of ligand binding to G protein coupled receptors: cannabinoid CB1, CB2 and adrenergic β 2 AR.
Latek D; Kolinski M; Ghoshdastider U; Debinski A; Bombolewski R; Plazinska A; Jozwiak K; Filipek S
J Mol Model; 2011 Sep; 17(9):2353-66. PubMed ID: 21365223
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid CB1 and CB2 receptor ligand specificity and the development of CB2-selective agonists.
Ashton JC; Wright JL; McPartland JM; Tyndall JD
Curr Med Chem; 2008; 15(14):1428-43. PubMed ID: 18537620
[TBL] [Abstract][Full Text] [Related]
10. Synthetic cannabinoids: analysis and metabolites.
Elsohly MA; Gul W; Wanas AS; Radwan MM
Life Sci; 2014 Feb; 97(1):78-90. PubMed ID: 24412391
[TBL] [Abstract][Full Text] [Related]
11. The application of 3D-QSAR studies for novel cannabinoid ligands substituted at the C1' position of the alkyl side chain on the structural requirements for binding to cannabinoid receptors CB1 and CB2.
Durdagi S; Kapou A; Kourouli T; Andreou T; Nikas SP; Nahmias VR; Papahatjis DP; Papadopoulos MG; Mavromoustakos T
J Med Chem; 2007 Jun; 50(12):2875-85. PubMed ID: 17521177
[TBL] [Abstract][Full Text] [Related]
12. Ligand-Assisted Protein Structure (LAPS): An Experimental Paradigm for Characterizing Cannabinoid-Receptor Ligand-Binding Domains.
Janero DR; Korde A; Makriyannis A
Methods Enzymol; 2017; 593():217-235. PubMed ID: 28750804
[TBL] [Abstract][Full Text] [Related]
13. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.
Klegeris A; Bissonnette CJ; McGeer PL
Br J Pharmacol; 2003 Jun; 139(4):775-86. PubMed ID: 12813001
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel class of selective human CB1 inverse agonists.
Foloppe N; Allen NH; Bentley CH; Brooks TD; Kennett G; Knight AR; Leonardi S; Misra A; Monck NJ; Sellwood DM
Bioorg Med Chem Lett; 2008 Feb; 18(3):1199-206. PubMed ID: 18083560
[TBL] [Abstract][Full Text] [Related]
15. Targeting the cannabinoid CB2 receptor: modelling and structural determinants of CB2 selective ligands.
Poso A; Huffman JW
Br J Pharmacol; 2008 Jan; 153(2):335-46. PubMed ID: 17982473
[TBL] [Abstract][Full Text] [Related]
16. Prediction of the Binding Affinities and Selectivity for CB1 and CB2 Ligands Using Homology Modeling, Molecular Docking, Molecular Dynamics Simulations, and MM-PBSA Binding Free Energy Calculations.
Ji B; Liu S; He X; Man VH; Xie XQ; Wang J
ACS Chem Neurosci; 2020 Apr; 11(8):1139-1158. PubMed ID: 32196303
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and testing of novel classical cannabinoids: exploring the side chain ligand binding pocket of the CB1 and CB2 receptors.
Nadipuram AK; Krishnamurthy M; Ferreira AM; Li W; Moore BM
Bioorg Med Chem; 2003 Jul; 11(14):3121-32. PubMed ID: 12818675
[TBL] [Abstract][Full Text] [Related]
18. C3-heteroaroyl cannabinoids as photolabeling ligands for the CB2 cannabinoid receptor.
Dixon DD; Tius MA; Thakur GA; Zhou H; Bowman AL; Shukla VG; Peng Y; Makriyannis A
Bioorg Med Chem Lett; 2012 Aug; 22(16):5322-5. PubMed ID: 22796181
[TBL] [Abstract][Full Text] [Related]
19. The endocannabinoid system as a target for alkamides from Echinacea angustifolia roots.
Woelkart K; Xu W; Pei Y; Makriyannis A; Picone RP; Bauer R
Planta Med; 2005 Aug; 71(8):701-5. PubMed ID: 16142631
[TBL] [Abstract][Full Text] [Related]
20. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study.
Montero C; Campillo NE; Goya P; Páez JA
Eur J Med Chem; 2005 Jan; 40(1):75-83. PubMed ID: 15642412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
